Computational approaches towards reducing contamination in single-cell RNA-seq data.
bioRxiv. 2020.

Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: A phase 2 randomized clinical trial.
JAMA Ophthalmology. 2021.PDF

Comparison of glaucoma-relevant transcriptomic datasets identifies novel drug targets for retinal ganglion cell neuroprotection.
Journal of Clinical Medicine. 2021.PDF

Neuroprotection in glaucoma: NAD+/NADH redox state as a potential biomarker and therapeutic target.
Cells. 2021.PDF

Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction.
Redox Biology. 2021.PDF

Targeting diet and exercise for neuroprotection and neurorecovery in glaucoma.
Cells. 2021.PDF

When is a control not a control? Reactive microglia occur throughout the control contralateral pathway of retinal ganglion cell projections in experimental glaucoma.
TVST. 2021.PDF

Retinal ganglion cell degeneration in a rat magnetic bead model of ocular hypertensive glaucoma.
TVST. 2021.PDF

Retinal ganglion cell degeneration correlates with hippocampal spine loss in experimental Alzheimer’s disease.
Acta Neuropathologica Communications. 2020.PDF

Potential therapeutic benefit of NAD+ supplementation for glaucoma and age-related macular degeneration.
Nutrients. 2020.PDF

Protrudin functions as a scaffold in the endoplasmic reticulum to support axon regeneration in the adult central nervous system.
Nature Communications. 2020.PDF

Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin.
PNAS. 2020.PDF

Complement peptide C3a receptor 1 promotes optic nerve degeneration in DBA/2J mice.
Journal of Neuroinflammation. 2020.PDF

Retinal energy metabolism in health and glaucoma.
Progress in Retinal and Eye Research. 2020.PDF

Ocular hypertension suppresses homeostatic gene expression in optic nerve head microglia of DBA/2 J mice.
Molecular Brain. 2020.PDF

OPA1 deficiency accelerates hippocampal synaptic remodelling and age-related deficits in learning and memory.
Brain Communications. 2020.PDF

Improvement in inner retinal function in glaucoma in response to nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial.
Clinical & Experimental Ophthalmology. 2020.PDF

Inhibition of monocyte-like cell extravasation protects from neurodegeneration in DBA/2J glaucoma.
Molecular Neurodegeneration. 2019.PDF

Targeting Metabolic Vulnerabilities for Neuroprotection in Glaucoma: B3 or not B3? That is the question.
Glaucoma Today. 2019.PDF

DOI: Link

Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma.
Brain Communications. 2019PDF

Nicotinamide treatment robustly protects from inherited mouse glaucoma.
Communicative & Integrative Biology. 2018.PDF

A multiethnic genome-wide association study of primary open-angle glaucoma identifies novel risk loci.
Nature Communications. 2018.PDF

Jnk2 deficiency increases the rate of glaucomatous neurodegeneration in ocular hypertensive DBA/2J mice.
Cell Death & Disease. 2018.PDF

Digestion of the glycosaminoglycan extracellular matrix by chondroitinase ABC supports retinal ganglion cell dendritic preservation in a rodent model of experimental glaucoma.
Molecular Brain. 2018.PDF

Neuroinflammation in glaucoma: A new opportunity.
Experimental Eye Research. 2017.PDF

Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.
Science. 2017.PDF

Nicotinamide and WLDS act together to prevent neurodegeneration in glaucoma.
Frontiers in Neuroscience. 2017.PDF

Early immune responses are independent of RGC dysfunction in glaucoma with complement component C3 being protective.
PNAS. 2017.PDF

GlyCAM1 negatively modulates monocyte entry into the optic nerve head and contributes to radiation-based protection in glaucoma.
Journal of Neuroinflammation. 2017.PDF

Glaucoma dialogue – 71509. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.
International Glaucoma Review. 2017.

DOI: Link

Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma.
Journal of Glaucoma. 2017.PDF

Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma.
Molecular Neurodegeneration. 2016.PDF

A miniature, fiber-coupled, wireless, deep-brain optogenetic stimulator.
Transactions on Neural Systems and Rehabilitation Engineering. 2015.PDF

Using genetic mouse models to gain insight into glaucoma: Past results and future possibilities.
Experimental Eye Research. 2015.PDF

Retinal ganglion cell dendritic degeneration in a mouse model of Alzheimer’s disease.
Neurobiology of Aging. 2013.PDF

Retinal ganglion cell dendritic atrophy in DBA/2J glaucoma.
PLoS One. 2013.PDF

Opa1 is essential for retinal ganglion cell synaptic architecture and connectivity.
Brain. 2012.PDF

Mouse models of dominant optic atrophy: What do they tell us about the pathophysiology of visual loss?
Vision Research. 2011.PDF

Specific deficits in visual electrophysiology in a mouse model of dominant optic atrophy.
Experimental Eye Research. 2011.PDF

Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy.
Brain. 2010.PDF